Sector News

Achaogen seeks near-term sale through bankruptcy process

April 16, 2019
Life sciences

Achaogen is looking to sell its assets and close out its affairs through the bankruptcy process. News of the Chapter 11 filing comes 10 months after Achaogen won FDA approval for its antibiotic Zemdri.

The run-up to the FDA approval of Zemdri proved to be the high watermark for Achaogen. While the FDA cleared Zemdri for use in complicated urinary tract infections, it rejected the drug in the treatment of bloodstream infections. That sent Achaogen into a downward spiral that led the company to lay off staff and seek a buyer for the business.

Now, five months after starting to search for a buyer, Achaogen has identified Chapter 11 bankruptcy as its best hope of getting some money for its assets.

“The Achaogen board of directors and management team have thoroughly assessed our strategic options and financial situation and unanimously agree that this structured sale process represents the best possible solution for the company,” Achaogen CEO Blake Wise said in a statement.

Notably, the process will allow buyers to acquire assets from Achaogen without taking on its debt and liabilities. Achaogen turned to debt to keep the business going when its plummeting stock price made raising money through share offerings less attractive.

Management at Achaogen thinks the $25 million in credit provided by Silicon Valley Bank will fund it through the Chapter 11 process. The first big milestone in the process comes when the window for submitting bids closes toward the end of May. A structured auction is due to start days later with a view to conclude the sale by mid-June.

The level of interest in Achaogen’s assets will depend on whether people think Zemdri can live up to the upbeat outlook that saw the biotech’s stock trade above $20 in 2017. Achaogen failed to deliver on expectations for the drug, but other products previously rescued from bankruptcy, such as Dendreon’s Provenge, have gone on to make significant sales.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.